DNB Asset Management AS Decreases Stock Holdings in Boston Scientific Corporation $BSX

DNB Asset Management AS cut its stake in Boston Scientific Corporation (NYSE:BSX) by 9.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 399,330 shares of the medical equipment provider’s stock after selling 42,244 shares during the period. DNB Asset Management AS’s holdings in Boston Scientific were worth $38,987,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of BSX. Choreo LLC increased its stake in Boston Scientific by 9.1% in the 3rd quarter. Choreo LLC now owns 58,122 shares of the medical equipment provider’s stock valued at $5,674,000 after purchasing an additional 4,836 shares in the last quarter. Mesirow Financial Investment Management Inc. grew its holdings in Boston Scientific by 5.5% in the third quarter. Mesirow Financial Investment Management Inc. now owns 3,420 shares of the medical equipment provider’s stock valued at $334,000 after purchasing an additional 178 shares during the last quarter. Interchange Capital Partners LLC increased its position in shares of Boston Scientific by 69.5% in the third quarter. Interchange Capital Partners LLC now owns 4,365 shares of the medical equipment provider’s stock valued at $426,000 after buying an additional 1,790 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Boston Scientific by 4.2% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,947,825 shares of the medical equipment provider’s stock worth $287,796,000 after buying an additional 119,815 shares during the last quarter. Finally, Citizens Business Bank purchased a new stake in shares of Boston Scientific in the 3rd quarter worth about $284,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BSX has been the subject of a number of research reports. Evercore cut their target price on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a research note on Friday, February 6th. Robert W. Baird lowered their target price on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. TD Cowen cut their price target on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Finally, Morgan Stanley dropped their price objective on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $108.36.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

BSX opened at $75.77 on Friday. Boston Scientific Corporation has a 1 year low of $72.69 and a 1 year high of $109.50. The company’s 50 day simple moving average is $87.69 and its 200 day simple moving average is $95.83. The stock has a market capitalization of $112.43 billion, a PE ratio of 39.06, a P/E/G ratio of 1.02 and a beta of 0.67. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.